Arvinas, Inc.
Overview
Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with innovative protein degradation therapeutics. The company's proprietary PROTAC® (Proteolysis Targeting Chimeras) technology leverages the body's own protein disposal system to target and degrade disease-causing proteins.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Arvinas, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.